

Invitation to presentation of Mendus' first quarter report 2024

Mendus AB ("Mendus" publ; IMMU.ST), will publish its interim report for the first quarter 2024 on Friday May 17 at 08:00 CEST. The company will host a live presentation the same day at 14:00 CEST. The call will be hosted by CEO Erik Manting and CFO Lotta Ferm. The presentation will be held in English and includes a Q&A session.

Date and time: Friday May 17 at 14:00 CEST

If you wish to participate via webcast please use the link below.

<https://ir.financialhearings.com/mendus-q1-report-2024>

If you wish to participate and ask questions via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference.

<https://conference.financialhearings.com/teleconference/?id=5006258>

For more information, please contact:

Erik Manting, CEO

E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>